SCHEMBL23914832

SCHEMBL23914832

COC(=O)C(=O)c1nn(COCCS(C)(C)C)c2ccccc2c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 3/20 0.36
HPGD P15428 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CNR2 P34972 1/20 0.34
PTGER4 P35408 2/20 0.33
TSHR P16473 1/20 0.33
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33
F2 P00734 1/20 0.33
PLAU P00749 1/20 0.33
ELANE P08246 1/20 0.33
HSD17B10 Q99714 1/20 0.32
MEN1 O00255 1/20 0.32
PKM P14618 1/20 0.32
ROCK1 Q13464 2/20 0.32
ROCK2 O75116 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23914597 0.91 ALDH1A1 (0.35) ALDH1A1KDM4EHPGDKMT2ALMNA
SCHEMBL23914498 0.81 KDM4E (0.41) ALDH1A1KDM4EHPGDKMT2ALMNA
SCHEMBL23915425 0.80 S1PR2 (0.36) ALDH1A1KDM4EHPGDKMT2ALMNA
SCHEMBL23914840 0.79 S1PR2 (0.38) ALDH1A1KDM4EHPGDKMT2ALMNA
SCHEMBL23914657 0.79 SMN1; SMN2 (0.36) ALDH1A1KDM4EHPGDKMT2ALMNA
SCHEMBL23914490 0.78 MAPT (0.44) KMT2ATSHRMAPTHSD17B10
SCHEMBL23915526 0.78 S1PR2 (0.46) ALDH1A1KDM4EHPGDKMT2ALMNA
SCHEMBL23914502 0.78 S1PR2 (0.36) ALDH1A1KDM4EHPGDKMT2ALMNA
SCHEMBL23914489 0.77 SLC16A3 (0.33) ALDH1A1KDM4EHPGDKMT2ALMNA
SCHEMBL23909128 0.77 NPC1 (0.43) ALDH1A1KDM4EHPGDKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GILEAD SCIENCES, INC. 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS S1PR1, S1PR3, S1PR2 ALDH1A1 944/4885KDM4E 3835/4885HPGD 2060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.